Von Willebrand disease is the commonest bleeding disorder encountered in the medical and surgical field. As a result of the repetitive bleeding into the joints many patients suffer from arthropathy that can cause a significant amount of pain and functional limitation. Total joint arthroplasty is being utilised as the last resort in managing these patients; however, the presence of von Willebrand disease raises a number of dilemmas. In this review, we look at the effects of von Willebrand disease on joints and the perioperative management of von Willebrand disease patients undergoing total joint arthroplasty.
Introduction
Advancements in the medical management of haematological pathologies improved the life expectancy of patients with these bleeding disorders. This imposes a rising challenge for orthopaedic surgeons performing major and invasive surgeries. With a prevalence of 1-2%, von Willebrand disease (VWD) is the commonest inherited haematological disorder worldwide (Franchini 2008 , Rodeghiero et al 1987 , Werner et al 1983 . It is considered to be a pathology of primary haemostasis caused by a qualitative or quantitative defect in von Willebrand factor (VWF), and in some cases it is considered to be a pathology of secondary haemostasis as a result of reduced numbers of clotting factor VIII (FVIII) (Windyga & von Depka-Prondzinski 2011) . VWF is a large glycoprotein that allows for platelet aggregation at the site of an injured blood vessel and it is responsible for securing FVIII (Gill et al 2011) . VWD is classified into three main types: two are quantitative problems related to a deficiency in VWF and one is a qualitative problem owing to a functional disorder of VWF. Type 1 is the most common (70-80%) and is a problem of quantity in which there is partial deficiency of VWF, type 3 is the complete absence of VWF and finally type 2 VWD is related to a functional disorder (Kahlon et al 2013 , Laffan et al 2014 . Patients with VWD may exhibit symptoms pertaining to bleeding into the skin, mucous membranes and may suffer from excessive bleeding during invasive procedures (Siboni et al 2014) . We discuss the perioperative management of patients with VWD undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA), and this should be taken in the context of local, regional and national guidelines (Laffan et al 2014) .
Von Willebrand disease in orthopaedic patients
From an orthopaedics point of view, VWD manifests as recurrent bleeding into the joints. As a result of this recurrent haemarthrosis, the articular cartilage in the joints is damaged due to the increased pressure, which leads to cartilage cell death (Rodriguez-Merchan 2014) . In addition, the repetitive insult of blood on the joint causes the synovial cells to proliferate and become inflamed (Cancienne et al 2015) . The combination of Division of Trauma & Orthopaedics Surgery, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK these elements eventually leads to fibrosis of the soft tissue surrounding the joint ultimately causing flexion contractures and bone deformity resulting in arthropathy (Cancienne et al 2015) . This clinically manifests as pain, reduced range of motion, impaired function and quality of life and eventually could lead to arthritis (RodriguezMerchan 2014 , Strauss et al 2017 . Van Galen et al (2013) concluded in his study that 12% of patients with arthropathy are secondary to recurrent haemarhtosis and that 19% of orthopaedic surgeries are related to repetitive haemarhtrosis. Due to the magnitude of damage inflicted on the joints, many patients undergo THA or TKA, which have been proven to improve pain and function of the joint (Cancienne et al 2015) .
Perioperative management of von Willebrand disease in total joint arthroplasty Rugeri et al (2016) compared VWD patients (n ¼ 19) to a control group (n ¼ 38) undergoing THA and TKA, it was concluded that there is no significant difference in the number of patients requiring intraoperative packed red blood cells (pRBCs) transfusion or the number of units transfused postoperatively. A feasible explanation for this is that the haematology department very strictly followed the VWD patients, which resulted in better outcomes. It is therefore evident that VWD patients should be approached in a multidisciplinary team to include haematologists, orthopaedic surgeons, anaesthetists and a specialist nurse (Cancienne et al 2015 , Wu et al 2017 . However, VWD patients undergoing any surgery are still at greater risk of bleeding and transfusion compared to the general population. Cancienne et al (2015) investigated TKA in 1,379 VWD patients versus a matched control of 394,657 patients. His results demonstrated that 453 (32.8%) VWD patients needed a significantly (P < 0.0001) higher amount of transfusion compared to 90,488 (22.9%) in the control group, this equated to an odds ratio of 1.6 (1.5-1.8) (95% CI). The normal VWF plasma levels ranges between 0.40 and 2.40iu/ml, values below <0.30iu/ml leads to bleeding (Laffan et al 2014) . All patients with VWD undergoing surgery should be investigated for FVIII using activated partial thromboplastin time or factor VIII activity (FVIII:C), VWF antigen (VWF:Ag) to measure the quantity of VWF, and VWF ristocetin cofactor activity (VWF:RCo) which assesses the ability of VWF to facilitate platelet adhesion (Laffan et al 2014) . Current practice and literature advocate for the prophylactic treatment of VWD patients prior to undergoing surgery to limit intraoperative blood loss. Rugeri et al (2016) compared the haemostatic outcomes of VWD patients (n ¼ 19) to a control group (n ¼ 38) undergoing THA and TKA. The mean (range) of approximated blood loss intraoperative was slightly more in the VWD group 427ml (70ml-1500ml) as opposed to the control patients 390ml (50ml-2000ml), this resulted in 32% of the VWD patients receiving intraoperative transfusions compared to 13% in the control group. In addition, 58% of VWD patients and 32% of the control patients met the International Society on Thrombosis and Haemostasis criteria for major bleeding, defined as the transfusion of two or more pRBCs (Schulman et al 2010) . Therapeutic management includes desmopressin and plasmaderived concentrates of FVIII and VWF (Kahlon et al 2013) . The main objective of this prophylactic haemostatic management is to ensure that VWF:RCo and FVIII reach a level of !1.0iu/ml preoperatively in order to limit the exaggerated blood loss in VWD patients (Laffan et al 2014) .
Postoperatively, it is recommended to stabilise VWF:RCo at >0.5iu/ml for six days (Mannucci et al 2013) . This will further aid in limiting postoperative blood loss, which would otherwise cause destruction at the bone-cement junction leading to prosthetic loosening (Nelson et al 1992) . Cancienne et al (2015) reported that 6.9% of the 1,379 VWD patients whom underwent TKA developed aseptic loosening at eight years follow-up. Because of this, the National Heart, Lung, and Blood Institute (NHLBI) advises that haemostatic management continues for 1-2 weeks postoperatively in VWD patients (Nichols et al 2008) .
Desmopressin therapy
Desmopressin is beneficial in patients with types 1 and 2 VWD, while plasma-derived VWF/FVIII concentrates are effective in managing patients with type 3 VWD and in patients who do not respond adequately to desmopressin (Siboni et al 2014) . Desmopressin has been proven to be successful at a dose of 0.3lg kg
À1
with an efficacy rate of 91% to 100%. Also, in the United Kingdom it has been licensed to be used subcutaneously, intranasally and intravenously (Franchini 2008 , Laffan et al 2014 , Rugeri et al 2016 . It is expected to increase plasma VWF and FVIII levels 3-5 times above baseline levels within half an hour of administration and could be given every 12-24h to ensure therapeutic levels of plasma VWF (Kahlon et al 2013). 
Plasma derivative VWF/FVIII concentrate

Infection
In addition to the haemostatic management of VWD patients perioperatively in TJA, it is essential to optimise patients against infections. The American Academy of Orthopaedic Surgeons states that cefazolin or cefuroxime should be utilised prophylactically within 60min prior to incising the skin in TJA and continued postoperatively for no longer than 24h (Illingworth et al 2013). Cancienne et al (2015) investigated TKA in 1,379 VWD patients versus a matched control of 394,657 patients, which revealed an infection rate of 2.9% within six months, in addition to periprosthetic infections within three and six months. Cancienne et al (2015) recommended limiting postoperative infections in VWD patients by encouraging sterility with selfinfusion of the replacement therapy, routine medical checkups and to inform the healthcare professionals of any infectious signs.
Venous thromboembolism
The gold standard postoperative prophylaxis for venous thromboembolism after THA or TKA is low molecular weight heparin (LMWH) as per the American College of Chest Physicians and the American Academy of Orthopedic Surgeons guidelines (Senay et al 2018) . Despite well-structured literature existing on VTE after TKA and THA in the general population, there has been a lack of similar data for patients with haematological disorders undergoing TKA/THA; therefore, the use of pharmacologic VTE prophylaxis is controversial (Franchini 2008 , Franchini et al 2009 , Rugeri et al 2016 . Literature suggests that patients with haematological disorders are assumed to have a low risk for postoperative VTE complications secondary to their bleeding pathology (Pradhan et al 2009); however, perioperative replacement therapy of VWD may preclude these patients to the risk of developing postoperative VTE (Dargaud et al 2004 , Koster et al 1995 
Conclusion
To conclude, von Willebrand disease leads to significant joint damage necessitating surgical intervention. Optimal perioperative management of these patients in a multidisciplinary setting is crucial to ensure a successful outcome and to limit complications.
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